Fulcrum Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $282.18M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | Apr 27, 2026 | Before market open | – | $-0.25 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | – | $-0.31 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | Before market open | – | $-0.31 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 29, 2025 | Before market open | – | $-0.28 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | – | $-0.31 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $0 | $-0.35 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | Before market open | $80.00M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 7, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Nov 13, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash, cash equivalents, and marketable securities | end 2024 | $240.00M | New |
| cash burn | full year 2025 | $55.00M to $65.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Fulcrum Therapeutics filed with the SEC
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimers This presentation (this “Presentation”) has been
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Other events · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Agreement terminated · Results of operations · Executive or director change · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Pociredir for Sickle Cell Disease Fast Track Designation Orphan Drug Designation
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pociredir PIONEER Study: 20 mg Cohort ASH Data Release December 7, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Pociredir for Sickle Cell Disease Fast Track Designation Orphan Drug Designation
Regulation FD disclosure · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Pociredir Pioneer Study: 12 mg Cohort Data Release July 29, 2025
Results of operations · Other events · EX-99.2 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
FULCRUM THERAPEUTICS Disclaimer and Notice This presentation contains
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in
Other events · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Material agreement · Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
F U L C R U M T H E R A P E U T I C S Disclaimer and Notice This
Regulation FD disclosure · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results
Results of operations · EX-99 to Form 8-K
Fulcrum Therapeutics Announces Pricing of Upsized
Material agreement · Other events · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Proposed Public
Results of operations · Other events · EX-99.1 to Form 8-K
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Pipeline and Catalysts Wholly Owned
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
Fulcrum Therapeutics Announces Recent Business Highlights
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Proposed Public
Material agreement · Other events · EX-99.1 to Form 8-K
Fulcrum Therapeutics Announces Pricing of Public
Material agreement · Other events · EX-99.2 to Form 8-K
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Fulcrum Therapeutics Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics ® Reports Recent Business Highlights and
Results of operations · EX-99.1 to Form 8-K
Fulcrum Therapeutics ® Announces Upcoming Milestones
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K